Tag Archives: (CVS)

How To Sell One Molecule Two Ways And Make Billions

Did you know Novo Nordisk’s (NVO) Ozempic and Wegovy are basically twins separated at birth? Both contain the same molecule — semaglutide — yet Wegovy costs three times more simply because it moonlights as a weight-loss drug instead of a diabetes treatment. That, my friends, is pharmaceutical sorcery so profitable it would make Merlin jealous. […]

Healthcare’s Falling Knife

While driving back from my nephew’s soccer game last weekend, I needed to pick up a prescription at my local pharmacy. The line was moving at glacial speed, so I struck up a conversation with the woman in front of me, who mentioned she worked as a nurse at a UnitedHealth-affiliated clinic. “Our patients are […]